Intensity Therapeutics is a phase 2 clinical-stage biotechnology company pioneering a new immune-based approach to treat solid tumor cancers. FDA and Intensity reached alignment on a phase 3 protocol design for soft tissue sarcoma during a meeting in 2021. Intensity leverages its DfuseRx(SM) technology platform to create new, proprietary drug formulations that, following direct injection, rapidly disperse throughout a tumor and diffuse therapeutic agents into cancer cells causing tumor necrosis. Intensity’s product candidates can induce an adaptive systemic immune response that not only attacks the injected tumor, but also non-injected tumors. The company was awarded a Cooperative Research and Development Agreement (“CRADA”) with the National Cancer Institute’s (“NCI”) Vaccine Branch in 2014 and has on-going phase 2 clinical partnerships with Merck and Bristol-Myers Squibb. For more information, visit the company’s website at www.IntensityTherapeutics.com.
To view the recorded fireside chat, visit https://www.fortressbiotech.com/news-media/events
To view IBN’s virtual coverage of Roth’s 34th Annual Conference, visit https://ibn.fm/Roth2022
About InvestorBrandNetwork’s Virtual Coverage
The InvestorBrandNetwork (“IBN”), a multifaceted financial news and publishing company, is providing the online investment community with a custom-built portal that includes summaries on each of the publicly traded companies participating virtually at Roth’s 34th Annual Conference. In addition to enabling proficient evaluation of each company via one-click access to market research tools and helpful website links, IBN is using social media and syndicated articles to maximize the visibility of the event.
For more than a decade, IBN has provided real-time coverage for numerous global events and conferences through its various brands, social media accounts and investment newsletters. To further expand visibility of participating companies at these events, and to ensure another successful year for its event collaborations, IBN’s syndication partners have extended digital coverage to include individual broadcasts on financial websites and platforms visited by millions of investors daily.
For more information, please visit https://www.InvestorBrandNetwork.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer
InvestorBrandNetwork (IBN)
Los Angeles, California
www.InvestorBrandNetwork.com
310.299.1717 Office
[email protected]